These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 15515753

  • 1. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma.
    Yamamoto F, Tsukamoto E, Nakada K, Takei T, Zhao S, Asaka M, Tamaki N.
    Ann Nucl Med; 2004 Sep; 18(6):519-26. PubMed ID: 15515753
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients.
    Van Den Bossche B, Lambert B, De Winter F, Kolindou A, Dierckx RA, Noens L, Van De Wiele C.
    Nucl Med Commun; 2002 Nov; 23(11):1079-83. PubMed ID: 12411836
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [SPECT-CT 67Ga studies in lymphoma disease. Contribution to staging and follow-up].
    Fuertes Manuel J, Estorch Cabrera M, Camacho Martí V, Flotats Giralt A, Rodríguez-Revuelto AA, Hernández Fructuoso MA, Carrió Gasset I.
    Rev Esp Med Nucl; 2006 Nov; 25(4):242-9. PubMed ID: 16827987
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
    Ömür Ö, Baran Y, Oral A, Ceylan Y.
    Diagn Interv Radiol; 2014 Nov; 20(2):185-92. PubMed ID: 24412817
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
    Kalff V, Hicks RJ, Ware RE, Greer B, Binns DS, Hogg A.
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL, Zhao JH, Wang C, He ZY, Wang TS, Xing Y.
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [Abstract] [Full Text] [Related]

  • 11. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U.
    Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
    [Abstract] [Full Text] [Related]

  • 12. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
    Mikosch P, Gallowitsch HJ, Zinke-Cerwenka W, Heinisch M, Pipam W, Eibl M, Kresnik E, Unterweger O, Linkesch W, Lind P.
    Acta Med Austriaca; 2003 Jul; 30(2):41-7. PubMed ID: 12752087
    [Abstract] [Full Text] [Related]

  • 13. Staging in childhood lymphoma: differences between FDG-PET and CT.
    Hermann S, Wormanns D, Pixberg M, Hunold A, Heindel W, Jürgens H, Schober O, Franzius C.
    Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722
    [Abstract] [Full Text] [Related]

  • 14. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
    Hong SP, Hahn JS, Lee JD, Bae SW, Youn MJ.
    Yonsei Med J; 2003 Oct 30; 44(5):779-86. PubMed ID: 14584092
    [Abstract] [Full Text] [Related]

  • 15. Vertebral photopenia on [67Ga]Ga-citrate and [18F]FDG PET/CT imaging in a patient with non-Hodgkin lymphoma.
    Meristoudis G, Ilias I, Giannakopoulos V.
    Nucl Med Rev Cent East Eur; 2023 Oct 30; 26(0):38-39. PubMed ID: 36353922
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of FDG-PET in malignant lymphoma.
    Becherer A, Jaeger U, Szabo M, Kletter K.
    Q J Nucl Med; 2003 Mar 30; 47(1):14-21. PubMed ID: 12714950
    [Abstract] [Full Text] [Related]

  • 17. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals.
    Sathekge M, Maes A, D'Asseler Y, Vorster M, Van de Wiele C.
    Nucl Med Commun; 2012 Jun 30; 33(6):581-90. PubMed ID: 22422098
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P, Zinzani P, Pourdehnad M, Alinari L, Nanni C, Farsad M, Battista G, Tani M, Stefoni V, Canini R, Monetti N, Rubello D, Alavi A, Franchi R, Fanti S.
    Eur J Nucl Med Mol Imaging; 2005 Jul 30; 32(7):749-56. PubMed ID: 15785956
    [Abstract] [Full Text] [Related]

  • 20. Determining the extent and stage of disease in patients with newly diagnosed non-Hodgkin's lymphoma using 18F-FDG-PET/CT.
    Papajik T, Myslivecek M, Skopalova M, Malan A, Buriankova E, Koza V, Hnatkova M, Trneny M, Sedova Z, Kubova Z, Koranda P, Flodr P, Jarkovsky J, Dusek L, Indrak K.
    Neoplasma; 2011 Jul 30; 58(4):291-7. PubMed ID: 21524147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.